HIV vaccine vCP1521

Drug Profile

HIV vaccine vCP1521

Alternative Names: ALVAC-HIV-vCP1521; Aventis Pasteur live recombinant ALVAC-HIV (vCP1521) priming vaccine + VaxGen gp120 B/E (AIDSVAX B/E) boosting vaccine; vCP1521

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-1-infections(In infants) in Uganda (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-1-infections(Prevention, In volunteers) in South Africa (IM, Injection)
  • 09 Jun 2015 HIV vaccine vCP1521 is still in phase II trials for HIV-infections (Prevention, In volunteers) in Thailand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top